BiotechTube
Altogen Biosystems

Altogen Biosystems

Austin, United States· Est.
altogen.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $2M

Overview

Altogen Biosystems leverages its expertise in polymer-stabilized liposomes, nanoparticles, and polymer chemistry to create optimized transfection solutions for delivering biomolecules like plasmid DNA, siRNA, mRNA, and proteins. Its technology has been cited in high-impact journals including Nature, Nature Medicine, and Nature Biotechnology, validating its research applications. The company operates a dual business model, selling proprietary transfection reagents while also offering comprehensive CRO services through Altogen Labs to support drug discovery and IND-enabling studies. Its strategic focus is on enabling gene function studies and therapeutic delivery across oncology, cardiovascular, metabolic, and infectious diseases.

OncologyCardiovascularMetabolic DisordersInfectious DiseasesNeurology

Technology Platform

Develops and manufactures advanced transfection reagents using polymer-stabilized liposomes, nanoparticles, and optimized polymer chemistry for efficient delivery of DNA, RNA, and proteins into specific cell lines and tissues in vivo.

Funding History

1
Total raised:$2M
Seed$2M

Opportunities

Growth is driven by increasing demand for specialized transfection tools in gene therapy and functional genomics research.
The integrated CRO service model (Altogen Labs) provides a significant cross-selling opportunity, creating a full-service pipeline from reagent to preclinical data for clients.
Expansion into new tissue targets and delivery modalities for in vivo applications represents a key R&D opportunity.

Risk Factors

Faces intense competition from large, diversified life science tool companies with greater resources.
Revenue is dependent on the cyclical R&D spending of academic and biopharma clients.
The lack of a proprietary therapeutic pipeline limits potential for blockbuster valuation growth compared to drug developers.

Competitive Landscape

Competes with giants like Thermo Fisher Scientific (Lipofectamine) and Promega in the broad transfection market. Differentiation is achieved through deep optimization for specific cancer cell lines, a focused suite of tissue-targeted in vivo reagents, and the unique integration with a preclinical CRO service, offering a validated end-to-end workflow for researchers.

More companies in Drug Delivery & Formulation →More companies in United States →